Status:
TERMINATED
Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
Suppression of stop mutations in the CFTR gene with parenteral gentamicin can be predicted in vitro and is associated with clinical benefit and significant modification of the CFTR-mediated chloride t...
Detailed Description
Background: This study was conducted to determine whether intravenous gentamicin can suppress stop codons in cystic fibrosis (CF) patients and, if so, whether it has any clinical benefits. Methods: W...
Eligibility Criteria
Inclusion
- cystic fibrosis with CFTR codon stop mutations
Exclusion
- Rhinitis
- nasal polyposis
- passive or active smoking
- modification of basal treatments within the previous month
- treatments with aminoglycosides within three previous months
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
End Date :
June 1 2005
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00376428
Start Date
January 1 2003
End Date
June 1 2005
Last Update
February 25 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Necker-Enfants malades
Paris, France, 75015